CJC-1295 With DAC (Drug Affinity Complex) is a synthetic analogue of growth hormone-releasing hormone (GHRH) that incorporates a lysine linker and a maleimidoproprionic acid (MPA) group enabling it to covalently bind to albumin in the bloodstream. This Drug Affinity Complex technology dramatically extends the peptide’s half-life from minutes to approximately 6-8 days, enabling sustained GHRH receptor stimulation over extended periods.
Researchers have studied CJC-1295 With DAC for its sustained elevation of GH and IGF-1 levels in preclinical animal models. Unlike native GHRH, which has a half-life of only a few minutes, the DAC modification allows researchers to study the effects of prolonged, continuous GHRH receptor stimulation. Research has examined how this altered pharmacokinetic profile affects the pattern of GH secretion compared to pulsatile GHRH delivery.
Studies have explored CJC-1295 With DAC’s dose-response relationship in rodent models, characterizing its effects on serum GH peaks and overall IGF-1 area under the curve. Researchers have compared it to non-DAC forms of CJC-1295 to understand the implications of continuous versus pulsatile GHRH signaling on pituitary biology. Its extended half-life makes it a unique research tool for longitudinal GH axis studies.
For research use only. Not for human consumption. Iron Prairie Labs products are intended for qualified researchers and laboratory use only.
